{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:55:42Z","timestamp":1776405342100,"version":"3.51.2"},"reference-count":61,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:00Z","timestamp":1776384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Neurosci."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Fragile X-associated tremor\/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disorder affecting carriers of premutation expansions (55\u2013200 CGG repeats) in the fragile X messenger ribonucleoprotein 1 (\n                      <jats:italic>FMR1<\/jats:italic>\n                      ) gene. Despite its clinical significance, FXTAS currently lacks reliable molecular markers for disease monitoring and evaluation of therapeutic efficacy.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      To address this critical gap, we performed an integrated multi-omics study combining plasma metabolomics (lipidomics, amine, and primary metabolites) with proteomics analyses in plasma and peripheral blood mononuclear cells (PBMCs) from FXTAS participants (\n                      <jats:italic>n<\/jats:italic>\n                      = 5, FXTAS stages 3\u20135) and age-matched non-carrier healthy controls (HC,\n                      <jats:italic>n<\/jats:italic>\n                      = 15).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Integrated analyses revealed molecular differences distinguishing FXTAS from HC, including alterations in metabolites related to energy metabolism (e.g., UDP-glucuronic acid, succinic acid, mannose), lipids (e.g., cholesterol, triglycerides, glycerophospholipids, ceramide), and selected amines (e.g., cystine, glycerophosphocholine, histidine). Proteomic analyses identified proteins associated with FXTAS clinical stage and CGG repeat size, implicating pathways related to mitochondrial function, immune-inflammatory signaling, and lipid metabolism. Comparative analysis of plasma and PBMC proteomes identified Basigin (CD147) and phospholipid transfer protein C2CD2 as overlapping candidate markers across biological matrices.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion<\/jats:title>\n                    <jats:p>Although limited by sample size and the cross-sectional design, this exploratory study demonstrates the value of integrated, cross-matrix multi-omics profiling for identifying molecular patterns associated with advanced FXTAS. These findings reinforce prior mechanistic models and provide a foundation for future validation in larger, longitudinal cohorts.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnmol.2026.1752903","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:19:48Z","timestamp":1776403188000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrated multi-omics profiling reveals novel molecular biomarkers and pathways associated with Fragile X-associated tremor\/ataxia syndrome"],"prefix":"10.3389","volume":"19","author":[{"given":"Marwa","family":"Zafarullah","sequence":"first","affiliation":[{"name":"Department of Biochemistry and Molecular Medicine, University of California, Davis","place":["Sacramento, CA, United States"]},{"name":"Department of Neurology and Neurological Sciences, Stanford School of Medicine","place":["Stanford, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Ponzini","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, School of Medicine, University of California, Davis","place":["Davis, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoungmi","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, School of Medicine, University of California, Davis","place":["Davis, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul J.","family":"Hagerman","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Medicine, University of California, Davis","place":["Sacramento, CA, United States"]},{"name":"MIND Institute, University of California, Davis","place":["Sacramento, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randi J.","family":"Hagerman","sequence":"additional","affiliation":[{"name":"MIND Institute, University of California, Davis","place":["Sacramento, CA, United States"]},{"name":"Department of Pediatrics, University of California, Davis","place":["Sacramento, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Flora","family":"Tassone","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Molecular Medicine, University of California, Davis","place":["Sacramento, CA, United States"]},{"name":"MIND Institute, University of California, Davis","place":["Sacramento, CA, United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1007\/s12311-021-01262-7","article-title":"Characterization of the cerebrospinal fluid proteome in patients with fragile X-associated tremor\/ataxia syndrome.","volume":"21","author":"Abbasi","year":"2022","journal-title":"Cerebellum"},{"key":"B2","doi-asserted-by":"publisher","first-page":"1898","DOI":"10.1212\/WNL.0b013e318271f7ff","article-title":"FXTAS: new insights and the need for revised diagnostic criteria.","volume":"79","author":"Apartis","year":"2012","journal-title":"Neurology"},{"key":"B3","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1007\/s12311-016-0776-y","article-title":"Majority of FXTAS cases present with intranuclear inclusions within purkinje cells.","volume":"15","author":"Ariza","year":"2016","journal-title":"Cerebellum"},{"key":"B4","doi-asserted-by":"publisher","first-page":"87","DOI":"10.4088\/jcp.v67n0112","article-title":"Psychiatric phenotype of the fragile X-associated tremor\/ataxia syndrome (FXTAS) in males: newly described fronto-subcortical dementia.","volume":"67","author":"Bacalman","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"B5","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/j.neuron.2019.12.015","article-title":"Deep multilayer brain proteomics identifies molecular networks in Alzheimer\u2019s disease progression.","volume":"105","author":"Bai","year":"2020","journal-title":"Neuron"},{"key":"B6","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/s41593-021-01006-0","article-title":"Answer ALS, a large-scale resource for sporadic and familial ALS combining clinical and multi-omics data from induced pluripotent cell lines.","volume":"25","author":"Baxi","year":"2022","journal-title":"Nat. Neurosci"},{"key":"B7","doi-asserted-by":"publisher","first-page":"2018","DOI":"10.1002\/mds.21493","article-title":"Fragile X-associated tremor\/ataxia syndrome: clinical features, genetics, and testing guidelines.","volume":"22","author":"Berry-Kravis","year":"2007","journal-title":"Mov. Disord."},{"key":"B8","doi-asserted-by":"publisher","first-page":"6277","DOI":"10.3390\/jcm14176277","article-title":"Parkinson\u2019s Disease through the lens of metabolomics: a targeted systematic review on human studies (2019-2024).","volume":"14","author":"Cannas","year":"2025","journal-title":"J. Clin. Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1038\/nrn3012","article-title":"Linking lipids to Alzheimer\u2019s disease: cholesterol and beyond.","volume":"12","author":"Di Paolo","year":"2011","journal-title":"Nat. Rev. Neurosci"},{"key":"B10","doi-asserted-by":"publisher","first-page":"a028035","DOI":"10.1101\/cshperspect.a028035","article-title":"Pathology of neurodegenerative diseases.","volume":"9","author":"Dugger","year":"2017","journal-title":"Cold Spring Harb. Perspect. Biol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1373\/clinchem.2009.136101","article-title":"A novel FMR1 PCR method for the routine detection of low abundance expanded alleles and full mutations in fragile X syndrome.","volume":"56","author":"Filipovic-Sadic","year":"2010","journal-title":"Clin. Chem"},{"key":"B12","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1242\/dmm.030205","article-title":"Neurodegenerative disease: models, mechanisms, and a new hope.","volume":"10","author":"Gitler","year":"2017","journal-title":"Dis. Model Mech"},{"key":"B13","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3389\/fnmol.2016.00071","article-title":"Plasma biomarkers for monitoring brain pathophysiology in FMR1 premutation carriers.","volume":"9","author":"Giulivi","year":"","journal-title":"Front. Mol. Neurosci"},{"key":"B14","doi-asserted-by":"publisher","first-page":"3871","DOI":"10.1042\/BCJ20160585","article-title":"Plasma metabolic profile delineates roles for neurodegeneration, pro-inflammatory damage and mitochondrial dysfunction in the FMR1 premutation.","volume":"473","author":"Giulivi","year":"","journal-title":"Biochem. J"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1021\/acs.jproteome.6b00049","article-title":"Novel metabolite biomarkers of Huntington\u2019s disease as detected by high-resolution mass spectrometry.","volume":"15","author":"Graham","year":"2016","journal-title":"J. Proteome Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1093\/brain\/awh683","article-title":"Neuropathology of fragile X-associated tremor\/ataxia syndrome (FXTAS).","volume":"129","author":"Greco","year":"2006","journal-title":"Brain"},{"key":"B17","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1038\/nrneurol.2016.82","article-title":"Fragile X-associated tremor\/ataxia syndrome - features, mechanisms and management.","volume":"12","author":"Hagerman","year":"2016","journal-title":"Nat. Rev. Neurol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1097\/WCO.0000000000000954","article-title":"Fragile X-associated tremor\/ataxia syndrome: pathophysiology and management.","volume":"34","author":"Hagerman","year":"2021","journal-title":"Curr. Opin. Neurol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/1866-1955-6-31","article-title":"Emerging topics in FXTAS.","volume":"6","author":"Hall","year":"2014","journal-title":"J. Neurodev. Disord"},{"key":"B20","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13059-017-1215-1","article-title":"Multi-omics approaches to disease.","volume":"18","author":"Hasin","year":"2017","journal-title":"Genome Biol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/metabo7030042","article-title":"Biomarker research in Parkinson\u2019s Disease using metabolite profiling.","volume":"7","author":"Havelund","year":"2017","journal-title":"Metabolites"},{"key":"B22","doi-asserted-by":"publisher","first-page":"600840","DOI":"10.3389\/fmolb.2020.600840","article-title":"Human cerebral cortex proteome of Fragile X-associated tremor\/ataxia syndrome.","volume":"7","author":"Holm","year":"2021","journal-title":"Front. Mol. Biosci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1352\/0895-80172004109<154:AIIWTF<2.0.CO;2","article-title":"Aging in individuals with the FMR1 mutation.","volume":"109","author":"Jacquemont","year":"2004","journal-title":"Am. J. Ment. Retard."},{"key":"B24","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1086\/374321","article-title":"Fragile X premutation tremor\/ataxia syndrome: molecular, clinical, and neuroimaging correlates.","volume":"72","author":"Jacquemont","year":"2003","journal-title":"Am. J. Hum. Genet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1016\/j.neuron.2007.07.020","article-title":"Pur alpha binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a Drosophila model of fragile X tremor\/ataxia syndrome.","volume":"55","author":"Jin","year":"2007","journal-title":"Neuron"},{"key":"B26","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/s41591-020-0815-6","article-title":"Large-scale proteomic analysis of Alzheimer\u2019s disease brain and cerebrospinal fluid reveals early changes in energy metabolism associated with microglia and astrocyte activation.","volume":"26","author":"Johnson","year":"2020","journal-title":"Nat. Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"186","DOI":"10.3389\/fneur.2019.00186","article-title":"An overview of MicroRNAs as biomarkers of ALS.","volume":"10","author":"Joilin","year":"2019","journal-title":"Front. Neurol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.3390\/ijms21041505","article-title":"Lipids and Alzheimer\u2019s Disease.","volume":"21","author":"Kao","year":"2020","journal-title":"Int. J. Mol. Sci"},{"key":"B29","doi-asserted-by":"publisher","first-page":"3695","DOI":"10.1038\/s41598-023-30892-6","article-title":"Integrated multi-omics analysis of Alzheimer\u2019s disease shows molecular signatures associated with disease progression and potential therapeutic targets.","volume":"13","author":"Kodam","year":"2023","journal-title":"Sci. Rep"},{"key":"B30","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1093\/hmg\/ddy410","article-title":"Metabolic pathways modulate the neuronal toxicity associated with fragile X-associated tremor\/ataxia syndrome.","volume":"28","author":"Kong","year":"2019","journal-title":"Hum. Mol. Genet"},{"key":"B31","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nn.4256","article-title":"Integrated genomics and proteomics define huntingtin CAG length-dependent networks in mice.","volume":"19","author":"Langfelder","year":"2016","journal-title":"Nat. Neurosci"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1212\/01.wnl.0000281692.98200.f5","article-title":"FMR1 CGG repeat length predicts motor dysfunction in premutation carriers.","volume":"70","author":"Leehey","year":"2008","journal-title":"Neurology"},{"key":"B33","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1002\/acn3.726","article-title":"A metabolomic approach to identifying biomarkers in blood of Alzheimer\u2019s disease.","volume":"6","author":"Lin","year":"2019","journal-title":"Ann. Clin. Transl. Neurol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/mds.20753","article-title":"Parkinsonism, dysautonomia, and intranuclear inclusions in a fragile X carrier: a clinical-pathological study.","volume":"21","author":"Louis","year":"2006","journal-title":"Mov. Disord"},{"key":"B35","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1038\/s41597-023-02598-x","article-title":"A multi-omics dataset for the analysis of frontotemporal dementia genetic subtypes.","volume":"10","author":"Menden","year":"2023","journal-title":"Sci. Data"},{"key":"B36","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.neuint.2009.09.003","article-title":"CD147, a gamma-secretase associated protein is upregulated in Alzheimer\u2019s disease brain and its cellular trafficking is affected by presenilin-2.","volume":"56","author":"Nahalkova","year":"2010","journal-title":"Neurochem. Int"},{"key":"B37","doi-asserted-by":"publisher","first-page":"3334","DOI":"10.1096\/fj.201600315R","article-title":"Warburg effect linked to cognitive-executive deficits in FMR1 premutation.","volume":"30","author":"Napoli","year":"2016","journal-title":"FASEB J"},{"key":"B38","doi-asserted-by":"publisher","first-page":"7174","DOI":"10.1002\/alz.14208","article-title":"Bridging the gap: multi-omics profiling of brain tissue in Alzheimer\u2019s disease and older controls in multi-ethnic populations.","volume":"20","author":"Reddy","year":"2024","journal-title":"Alzheimers Dement"},{"key":"B39","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1038\/ejhg.2009.51","article-title":"Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families.","volume":"17","author":"Rodriguez-Revenga","year":"2009","journal-title":"Eur. J. Hum. Genet"},{"key":"B40","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.3390\/cells12172132","article-title":"Brain metabolomics in Fragile X-associated tremor\/ataxia syndrome (FXTAS).","volume":"12","author":"Salcedo-Arellano","year":"2023","journal-title":"Cells"},{"key":"B41","doi-asserted-by":"publisher","first-page":"105580","DOI":"10.1016\/j.nbd.2021.105580","article-title":"Multi-omic insights into Parkinson\u2019s Disease: from genetic associations to functional mechanisms.","volume":"163","author":"Schilder","year":"2022","journal-title":"Neurobiol. Dis"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1038\/emboj.2010.21","article-title":"Sam68 sequestration and partial loss of function are associated with splicing alterations in FXTAS patients.","volume":"29","author":"Sellier","year":"2010","journal-title":"EMBO J"},{"key":"B43","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s13024-018-0304-2","article-title":"Recent advances and perspectives of metabolomics-based investigations in Parkinson\u2019s disease.","volume":"14","author":"Shao","year":"2019","journal-title":"Mol. Neurodegener"},{"key":"B44","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1038\/s41588-018-0129-5","article-title":"Genetic identification of brain cell types underlying schizophrenia.","volume":"50","author":"Skene","year":"2018","journal-title":"Nat. Genet"},{"key":"B45","doi-asserted-by":"publisher","first-page":"548","DOI":"10.2119\/molmed.2016.00122","article-title":"Altered redox mitochondrial biology in the neurodegenerative disorder fragile X-tremor\/ataxia syndrome: use of antioxidants in precision medicine.","volume":"22","author":"Song","year":"2016","journal-title":"Mol. Med"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1177932219899051","DOI":"10.1177\/1177932219899051","article-title":"Multi-omics data integration, interpretation, and its application.","volume":"14","author":"Subramanian","year":"2020","journal-title":"Bioinform. Biol. Insights"},{"key":"B47","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41591-018-0223-3","article-title":"Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia.","volume":"25","author":"Swarup","year":"2019","journal-title":"Nat. Med"},{"key":"B48","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/j.1601-183X.2012.00779.x","article-title":"Neuropathological, clinical and molecular pathology in female fragile X premutation carriers with and without FXTAS.","volume":"11","author":"Tassone","year":"2012","journal-title":"Genes Brain Behav"},{"key":"B49","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1086\/302720","article-title":"Elevated levels of FMR1 mRNA in carrier males: a new mechanism of involvement in the fragile-X syndrome.","volume":"66","author":"Tassone","year":"2000","journal-title":"Am. J. Hum. Genet"},{"key":"B50","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2353\/jmoldx.2008.070073","article-title":"A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations.","volume":"10","author":"Tassone","year":"2008","journal-title":"J. Mol Diagn"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.3390\/cells12182330","article-title":"Insight and recommendations for fragile X-premutation-associated conditions from the fifth international conference on FMR1 premutation.","volume":"12","author":"Tassone","year":"2023","journal-title":"Cells"},{"key":"B52","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/ana.21948","article-title":"RNA-mediated neurodegeneration in repeat expansion disorders.","volume":"67","author":"Todd","year":"2010","journal-title":"Ann. Neurol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41582-019-0301-2","article-title":"LRRK2 in Parkinson disease: challenges of clinical trials.","volume":"16","author":"Tolosa","year":"2020","journal-title":"Nat. Rev. Neurol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"48","DOI":"10.15252\/emmm.201708202","article-title":"A proteomic network approach across the ALS-FTD disease spectrum resolves clinical phenotypes and genetic vulnerability in human brain.","volume":"10","author":"Umoh","year":"2018","journal-title":"EMBO Mol. Med"},{"key":"B55","doi-asserted-by":"publisher","first-page":"eadf9717","DOI":"10.1126\/sciadv.adf9717","article-title":"A simple, time- and cost-effective, high-throughput depletion strategy for deep plasma proteomics.","volume":"9","author":"Viode","year":"2023","journal-title":"Sci. Adv"},{"key":"B56","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.neuron.2020.01.004","article-title":"Genome-wide In Vivo CNS screening identifies genes that modify CNS neuronal survival and mHTT toxicity.","volume":"106","author":"Wertz","year":"2020","journal-title":"Neuron"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1002\/acn3.52040","article-title":"Mitochondrial dysfunction in brain tissues and extracellular vesicles fragile X-associated tremor\/ataxia syndrome.","volume":"11","author":"Yao","year":"2024","journal-title":"Ann. Clin. Transl. Neurol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"691717","DOI":"10.3389\/fpsyt.2021.691717","article-title":"Metabolomic biomarkers are associated with area of the pons in fragile X premutation carriers at risk for developing FXTAS.","volume":"12","author":"Zafarullah","year":"2021","journal-title":"Front. Psychiatry"},{"key":"B59","doi-asserted-by":"publisher","first-page":"13477","DOI":"10.3390\/ijms241713477","article-title":"Blood proteome profiling reveals biomarkers and pathway alterations in fragile X PM at risk for developing FXTAS.","volume":"24","author":"Zafarullah","year":"2023","journal-title":"Int. J. Mol. Sci"},{"key":"B60","doi-asserted-by":"publisher","first-page":"16676","DOI":"10.1096\/fj.202001880R","article-title":"Metabolic profiling reveals dysregulated lipid metabolism and potential biomarkers associated with the development and progression of Fragile X-Associated Tremor\/Ataxia Syndrome (FXTAS).","volume":"34","author":"Zafarullah","year":"2020","journal-title":"FASEB J"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2138","DOI":"10.2174\/0929867321666131227163352","article-title":"CD147: a novel modulator of inflammatory and immune disorders.","volume":"21","author":"Zhu","year":"2014","journal-title":"Curr. Med. Chem"}],"container-title":["Frontiers in Molecular Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnmol.2026.1752903\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T05:19:50Z","timestamp":1776403190000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnmol.2026.1752903\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,17]]},"references-count":61,"alternative-id":["10.3389\/fnmol.2026.1752903"],"URL":"https:\/\/doi.org\/10.3389\/fnmol.2026.1752903","relation":{},"ISSN":["1662-5099"],"issn-type":[{"value":"1662-5099","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,17]]},"article-number":"1752903"}}